Ananda CEO outlines progress with trials, strengthened structure and improved investor sentiment

Proactive - Interviews for investors

Ananda Developments CEO Melissa Sturgess discussed the company's recent advancements in CBD-based drug development with Proactive's Stephen Gunnion. Sturgess highlighted the progress of its clinical trials and the increasing understanding of CBD's potential in the pharmaceutical industry. She also discussed the growing distinction between over-the-counter CBD products and those being developed by Ananda, emphasising the regulatory pathway necessary for CBD medicines. Sturgess highlighted two phase two clinical trials, focusing on chemotherapy-induced pain and endometriosis, initiated by clinicians responding to patient needs. She explained the challenges and benefits of getting CBD drugs approved by the MHRA and available on the NHS, aiming to make these drugs accessible to all patients. Discussing the company's portfolio, Sturgess shared insights on their pre-clinical study using MRX1 in mice and the importance of breadth and depth in the company's research. She also talked about strengthening the company's top structure with the appointment of a scientific advisory board, chaired by Professor Clive Page, and new members, Professors Trevor Jones and Cherry Wainwright. Sturgess concluded by outlining the milestones shareholders should look for, including clinical trial progress and further study results. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AnandaDevelopments #CBDDrugs #ClinicalTrials #MelissaSturgess #Pharmaceuticals #CBDResearch #MHRA #NHS #InvestingInPharma #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews